Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + leucovorin + oxaliplatin + epirubicin + etoposide
- Development stage
- Unknown
- Lead developer
- Research Institute of General Surgery, Jinling Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The combination of fluorouracil, leucovorin, oxaliplatin, epirubicin, and etoposide, commonly known as the EOELF regimen, is an intensive chemotherapy protocol developed by the Research Institute of General Surgery at Jinling Hospital for the treatment of advanced gastric cancer. This five-drug regimen integrates multiple cytotoxic mechanisms to maximize therapeutic efficacy: epirubicin (an anthracycline) and etoposide (a podophyllotoxin derivative) inhibit topoisomerase II and induce DNA damage; oxaliplatin (a third-generation platinum agent) forms bulky DNA adducts and cross-links; 5-fluorouracil (an antimetabolite) inhibits thymidylate synthase to disrupt DNA synthesis; and leucovorin (folinic acid) acts as a biochemical modulator that stabilizes the binding of 5-fluorouracil to its target enzyme. Primarily investigated in Phase II clinical trials, the EOELF regimen aims to improve response rates and survival in patients with metastatic or unresectable gastric malignancies.
- Other names
- EOELF regimenepirubicin, etoposide, oxaliplatin, 5-fluorouracil and leucovorin
02
Targets
TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on fluorouracil + leucovorin + oxaliplatin + epirubicin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + leucovorin + oxaliplatin + epirubicin + etoposide.